Oncology Penny Stocks

US-listed oncology penny stocks priced $0.50 to $5, ranked by today's percentage change. Cancer-focused drug developers, immuno-oncology, radioligand therapy, ADC platforms, CAR-T, and oncology-diagnostics plays. Updated intraday.

Data as of 5/30/2026 11:38:07 PM · Intraday prices · 106 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1APMAptorum Group Limited Class A Ordinary SharesHealthcare$1.0400+24.10%456K
2INDPIndaptus Therapeutics, Inc. Common StockHealthcare$1.7700+22.92%103K
3CCCCC4 Therapeutics, Inc.Healthcare$4.3900+19.95%5.9M
4SLXNSilexion Therapeutics Corp Ordinary SharesHealthcare$4.9900+16.70%313K
5ONCYOncolytics Biotech, Inc. Common SharesHealthcare$1.0500+12.30%2.9M
6GLMDGalmed Pharmaceuticals Ltd.Healthcare$0.7500+10.70%273K
7PPCBPropanc Biopharma, Inc. Common StockHealthcare$1.8650+9.71%68K
8ATNMActinium Pharmaceuticals, IncHealthcare$1.2600+9.57%185K
9CRISCuris IncHealthcare$0.5648+7.91%366K
10MAIAMAIA Biotechnology, Inc.Healthcare$1.3909+7.83%1.1M
11FATEFate Therapeutics, Inc.Healthcare$2.8350+7.80%5.2M
12OSTXOS Therapies IncorporatedHealthcare$2.1200+7.07%1.5M
13MBIOMustang Bio, Inc.Healthcare$0.6731+6.17%41K
14SANASana Biotechnology, Inc. Common StockHealthcare$3.3150+5.91%5.0M
15CVMCel-Sci CorporationHealthcare$1.5600+5.41%189K
16TLSITriSalus Life Sciences, Inc. Common StockHealthcare$3.4300+4.89%337K
17INABIN8bio, Inc. Common StockHealthcare$1.8700+3.89%94K
18CRDFCardiff Oncology, Inc. Common StockHealthcare$1.9100+3.80%786K
19MRKRMarker Therapeutics, Inc. Common StockHealthcare$1.5650+3.64%92K
20GDTCCytoMed Therapeutics Limited Ordinary SharesHealthcare$1.1800+3.51%24K
21ENGNenGene Therapeutics Inc. Common StockHealthcare$1.8400+3.37%1.1M
22ONCOOnconetix, Inc. Common StockHealthcare$1.2050+2.99%682K
23CELUCelularity Inc. Class A Common StockHealthcare$1.0200+2.93%75K
24IPSCCentury Therapeutics, Inc. Common StockHealthcare$2.4500+2.73%1.2M
25AGENAgenus Inc.Healthcare$3.4900+2.65%617K
26CLRBCellectar Biosciences INC NEWHealthcare$3.2200+2.55%278K
27LTRNLantern Pharma Inc. Common StockHealthcare$3.5800+2.29%117K
28OKUROnKure Therapeutics, Inc. Class A Common StockHealthcare$4.2100+2.18%89K
29LNAILunai Bioworks Inc. Common StockHealthcare$3.1000+1.97%135K
30PDSBPDS Biotechnology Corporation Common Stock$1.0900+1.87%827K
31MBRXMoleculin Biotech, Inc.Healthcare$2.7900+1.83%366K
32CTXRCitius Pharmaceuticals Inc. CommonHealthcare$0.6643+1.75%380K
33CRBUCaribou Biosciences, Inc. Common StockHealthcare$2.3500+1.73%1.4M
34PYXSPyxis Oncology, Inc. Common StockHealthcare$1.8100+1.69%299K
35PLRXPliant Therapeutics, Inc. Common StockHealthcare$1.2700+1.60%315K
36ALXOALX Oncology Holdings Inc. Common StockHealthcare$1.9200+1.59%705K
37BIAFbioAffinity Technologies, Inc. Common StockHealthcare$1.6750+1.52%88K
38APREAprea Therapeutics, Inc. Common stockHealthcare$0.9435+1.40%124K
39XBIOXenetic Biosciences, Inc.Healthcare$3.1200+1.30%6K
40IBOImpact BioMedical, Inc.Healthcare$0.5197+1.09%28K
41CNTXContext Therapeutics Inc. Common StockHealthcare$2.8600+1.06%552K
42TCRXTScan Therapeutics, Inc. Common StockHealthcare$1.0900+0.93%208K
43PMVPPMV Pharmaceuticals, IncHealthcare$1.2000+0.84%410K
44VSTMVerastem, Inc.Healthcare$4.3250+0.82%2.1M
45ANIXAnixa Biosciences, Inc.Healthcare$2.7200+0.74%94K
46ANIXAnixa Biosciences, Inc.Healthcare$2.7200+0.74%94K
47LSTALisata Therapeutics, Inc. Common StockHealthcare$3.3200+0.61%1.8M
48INMBINmune Bio Inc. Common stockHealthcare$1.42000.00%303K
49PRLDPrelude Therapeutics IncorporatedHealthcare$3.93000.00%288K
50GNLXGenelux Corporation Common StockHealthcare$3.07000.00%115K

Trading Sub-$5 Oncology

Oncology is the most catalyst-rich corner of biotech. Cancer trials produce frequent readouts, FDA decisions are highly visible, and a single Phase 1/2 hit can rerate a company 500-1,500%. The flip side: clinical holds and failed primary endpoints can wipe out 60-90% in a session. This is binary-event trading at its purest.

  • ASCO & ESMO conferences: major oncology conferences (May, September, June) are catalyst-dense windows. Abstracts publish 3-4 weeks before the meeting.
  • PDUFA dates: FDA action dates for cancer drugs are scheduled events — visible on FDA.gov.
  • Trial readout calendar: companies pre-announce expected readout windows; the windows themselves are the trade setup.
  • Indication breadth: companies with multiple cancer indications are more durable than single-asset plays. Platform technologies (ADCs, radioligands, bispecifics) command premiums.
  • Survival endpoints: overall survival (OS) is the gold standard; surrogate endpoints (PFS, response rate) are weaker. Pay attention to which the trial used.
  • Partnership leverage: a Big Pharma licensing deal can revalue a sub-$5 oncology company overnight.
  • Dilution constant: oncology development is expensive. Most sub-$5 names raise capital every 6-18 months — see our dilution explainer.
  • Halt risk on readout days: volatility halts (LUDP) are routine on trial-data days — see our halt guide.

See also: biotech penny stocks (broader), genomics penny stocks, penny stocks under $1.